

DEXMEDETOMIDINE

Trade Name	Precedex® Pfizer																		
Class	Selective alpha2-adrenergic agonist																		
Mechanism of Action	Dexmedetomidine activates guanine –nucleotide regulatory binding proteins (G-Proteins) which in turn decrease cAMP resulting in modulation of ion channel activity in alpha2 adrenergic receptors. The presynaptic effect on alpha 2 adrenergic receptors is to inhibit release of noradrenaline which prevents transmission of pain signals. The inhibitory effect on postsynaptic neuronal receptors in the brain and spinal cord is to cause hypotension, bradycardia, sedation and analgesia. In other areas of the body dexmedetomidine causes decreased saliva production, alterations in bowel motility, contraction of vascular and other smooth muscle, increased renal secretion of water and sodium, decreased intraocular pressure and reduced insulin release by the pancreas. ¹																		
Indication	Sedative, opioid sparing agent																		
Contraindications	Use with caution with hypotension, bradycardia, ventricular dysfunction, hypovolaemia, diabetes, renal/hepatic impairment.																		
Supplied As	200 microgram / 2 mL vial																		
Dilution	IV: <table border="1" data-bbox="517 1102 1458 1290"> <thead> <tr> <th>Drug</th> <th>0.9% Saline Added</th> <th>Final Volume</th> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td>100mcg (1 mL)</td> <td>49 mL</td> <td>50mL</td> <td>2 microgram/mL</td> </tr> </tbody> </table> IV: Double Strength <table border="1" data-bbox="517 1366 1458 1554"> <thead> <tr> <th>Drug</th> <th>0.9% Saline Added</th> <th>Final Volume</th> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td>200mcg (2 mL)</td> <td>48 mL</td> <td>50mL</td> <td>4 microgram/mL</td> </tr> </tbody> </table>			Drug	0.9% Saline Added	Final Volume	Concentration	100mcg (1 mL)	49 mL	50mL	2 microgram/mL	Drug	0.9% Saline Added	Final Volume	Concentration	200mcg (2 mL)	48 mL	50mL	4 microgram/mL
Drug	0.9% Saline Added	Final Volume	Concentration																
100mcg (1 mL)	49 mL	50mL	2 microgram/mL																
Drug	0.9% Saline Added	Final Volume	Concentration																
200mcg (2 mL)	48 mL	50mL	4 microgram/mL																
Dosage	Continous infusion: Preterm <37 weeks: 0.2 – 1 microgram/kg/hr Term: 0.3 - 1.5 microgram/kg/hr Dose Initiation: Start at the lower end of the dosing range and increase in steps of 0.1 – 0.2 microgram/kg/hour every hour until effect achieved Dose Weaning: Wean dose by 0.1 – 0.2 microgram/kg/hr every 12-24 hours, unless it has been running for <24 hours when no weaning is needed																		
Guardrails	Min Conc: 1 microgram/mL Max Conc: 4 microgram/mL Soft Min: 0.03 microgram/kg/hr Hard Max: 1.5 microgram/kg/hr Soft Max: 1.2 microgram/kg/hr Default: 0.2 microgram/kg/hr																		

Administration	Demedetomidine is used in NICU for sedation and as an opioid sparing agent. To avoid rebound side effects the infusion needs to be weaned before stopping. The only exception to this is if the infusion has been running for <24 hours and then it can be stopped without weaning.
Compatible with	Solution: Glucose 5% and Sodium chloride 0.9% Y-site: aciclovir, adrenaline, allopurinol, amikacin, aminophylline, amiodarone amphotericin B liposomal, ampicillin, atenolol , atropine sulfate, azithromycin, aztreonam, buprenorphine hydrochloride, calcium chloride, calcium gluconate cefazolin, cefepime, cefotaxime, cefoxitin ceftazidime, cefuroxime, ciprofloxacin, clindamycin , dexamethasone, digoxin, dobutamine, dopamine, ephedrine sulfate, erythromycin, fentanyl, fluconazole, gentamicin, heparin, imipenem/cilastatin, insulin, lipid, magnesium sulfate , mannitol meropenem, methylprednisolone, metoclopramide, metronidazole , midazolam , morphine, naloxone, noradrenaline, octreotide, pancuronium, phenobarbital, phenylephrine , piperacillin/tazobactam potassium chloride , potassium phosphates , procainamide, prochlorperazine, promethazine, propofol, propranolol, ranitidine , remifentanyl, rocuronium, sodium acetate, sodium bicarbonate, sodium phosphates, sulfamethoxazole/trimethoprim, tacrolimus, teniposide, theophylline, thiopental sodium, ticarcillin/clavulanate, tobramycin, TPN, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, verapamil, voriconazole, zidovudine.
Incompatible with	Amphotericin B conventional, colloidal, amphotericin B lipid complex, diazepam, garenoxacin, gemtuzumab, irinotecan, pantoprazole, phenytoin.
Interactions	Increased risk of hypotension when used concurrently with propofol or midazolam. Enhancement of effects expected when used in combination with sedative, hypnotics and opioids
Monitoring	Heart rate, blood pressure, oxygen saturation, respiratory rate, urine output.
Stability	Store at room temperature.
Storage	Single use, discard any remaining contents of the vial after opening
Adverse Reactions	Bradycardia, hypotension, sinus arrest, (with rapid infusion). Fever, nausea, vomiting, atrial fibrillation, anaemia, leucocytosis, oliguria, hypoxia, pulmonary oedema, pleural effusion, thirst. Withdrawal and rebound symptoms (hypertension, agitation, tachycardia, dilated pupils, diarrhoea, increased muscle tone, emesis)
Metabolism	Metabolised by the liver, metabolites 95% excreted in urine 4% in faeces. It is unknown whether metabolites are active. Half life of parent compound = 6 minutes, metabolite = 2 hours.

<p>References</p>	<ol style="list-style-type: none"> 1. http://www.micromedexsolutions.com/micromedex2/librarian/# 2. Drug Profile: Dexmedetomidine KEMH and PCH Pharmacy Neonatal Clinical Care Unit. Dept of Health Western Australia 2017 3. Finkel JC and Elrefai A The use of dexmedetomidine to facilitate Opioid and Benzodiazepine detoxification in an infant. <i>Anesth Analg</i> 2004;98:1658-9 4. Carter BS and Brunkhorst J. Neonatal Pain Management. www.seminperinat.com 5. Whalen LD, DiGennaro JL, IrbyGA et al. Longterm dexmedetomidine use and safety profile among critically ill children and neonates. <i>Pediatr Crit Care Med</i>. 2014 Oct;15(8):706-14. 6. Chrysostomou C, Schulman SR, Herrera Castellanos M, Cofer BE, Mitra S, da Rocha MG, Wisemandle WA, Gramlich L. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. <i>J Pediatr</i>. 2014;164:276-82.e1-3. 7. Potts AL, Anderson BJ, Warman GR, Lerman J, Diaz SM, Vilo S. Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. <i>Paediatr Anaesth</i>. 2009;19:1119-29. 8. Potts AL, Warman GR, Anderson BJ. Dexmedetomidine disposition in children: a population analysis. <i>Paediatr Anaesth</i>. 2008;18:722-30. 9. www.uptodate.com 10. www.anmfonline.org 11. Campos-Baeta Y. et al Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition. <i>Nutrition in Clinical Practice</i>. Sep 2019. https://doi.org/10.1002/ncp.10391
<p>Updated By</p>	<p>A Lynn, B Robertshawe Jan 2018 A Lynn, M Wallenstein, B Robertshawe May 2021 A Lynn, B Robertshawe May 2023 (change concentration) Aug 2023 (compatibility with TPN/Lipid)</p>